Dáil Éireann Debate, Thursday - 20 September 2018
163. Deputy Charlie McConalogue asked the Minister for Health the status of the HSE's investigations into the provision of a drug (details supplied); and if he will make a statement on the matter. [38205/18]
Amharc ar fhreagraThe HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
As noted in Parliamentary Question 19115/18, the HSE received a new reimbursement application for the reimbursement of Sativex from the manufacturer in February 2018. A rapid review by the NCPE was completed on 3 April 2018 and a full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex compared with the current standard of care.
The full pharmacoeconomic assessment was commissioned by the HSE on 20 April 2018.
